Non Small Cell Lung CancerCURTAINNCT07673861
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
A study testing Marsden360 ctDNA test and GTAB review in people with Non Small Cell Lung Cancer and Gastrointestinal Stromal Tumor (GIST), run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer
- What is being tested?
- Marsden360 ctDNA test and GTAB review
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 23 May 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All cohorts:
- Age ≥18 years old
- Ability to provide written informed consent
- Presence of metastatic or unresectable disease
- Being reviewed and treated through medical oncology service at Royal Marsden Hospital
- Cohort 1: Locally Advanced/Metastatic NSCLC
Show all 22Show fewer
- Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND
- Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
- Cohort 2: Locally Advanced/Metastatic GIST
- Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND
- Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
- Cohort 3: Metastatic Colorectal Cancer
- Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND
- If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent
- If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent
- Cohort 4: Locally Advanced/Metastatic BTC
- Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency [dMMR]), AND
- Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent
- Cohort 5: Advanced/Metastatic ovarian cancer
- Diagnosis of advanced/metastatic high-grade ovarian cancer, AND
- Known BRCA status, AND
- Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent
Who cannot join
- All cohorts:
- Medically unstable to commit to sampling required for the study
- ECOG performance status ≥3
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Royal Marsden NHS Foundation Trust
London
Rebecca Brooks, +44 208 642 6011, rebecca.brooks@rmh.nhs.uk
Simon Connolly, +44 208 642 6011, simon.connolly@rmh.nhs.uk
About this study
Official title: Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine: A Tumour Agnostic Study
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease).
The aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK).
Read more
One hundred patients will be recruited, with 20 from each of the following cancer types:
- Non-small cell lung cancer
- Gastrointestinal stromal tumours
- Colorectal cancer
- Biliary tract cancer
- Ovarian cancer.
Patients must be aged 18 or over, must have had progressive disease whilst receiving anti-cancer treatment, and must be being treated at The Royal Marsden.
Patients will have a blood sample taken and analysed using the Marsden360 ctDNA test. The results of the test will be looked at by The Royal Marsden Genomic Tissue Advisory Board (GTAB), and for each individual patient, the GTAB will determine if having a ctDNA test helped to personalise their care by:
- Aiding the identification of a genomically-matched standard of care therapy
- Aiding the identification of a genomically-matched clinical trial (based in the UK)
- Offering additional prognostic information not otherwise available through standard of care testing
- Negating the need for a tissue biopsy.
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer, Ovarian Cancer
- Being tested
- Marsden360 ctDNA test and GTAB review
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Gastrointestinal Stromal Tumors, Colorectal Neoplasms, Biliary Tract Neoplasms, Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Marsden360 ctDNA test and GTAB reviewDiagnostic test
Participant blood samples will analysed using the Marsden360 ctDNA test. Results will subsequently be reviewed by the Royal Marsden Genomic Tumour Advisory Board (GTAB). The GTAB will use the results of the test to try to identify a genomically-matched standard of care therapy, to identify a genomically-matched clinical trial (based in the UK), to offer additional prognositc information not otherwise available through standard of case, or determine if the need for a tissue biopsy is negated.
| Study group | Role | What they receive |
|---|---|---|
| Patients who have had progressive disease on therapy within the 6 weeks prior to consent | Other | Not described Receives: Diagnostic Test: Marsden360 ctDNA test and GTAB review |
What is being measured
The primary outcome is the main question the study is designed to answer.
The number (%) of patients in whom ctDNA result was deemed to be clinically useful at the time of progression on prior line of therapy
This is a composite outcome measure, where the results of ctDNA testing performed at the time of progressive disease led to at least one of the following (to be determined by the GTAB):
- Identification of a genomically-matched SOC therapy, or
- Identification of a genomically-matched clinical trial (based in the UK), or
- Offered additional prognostic information not otherwise available through SOC, or
- Negated the need for a tissue biopsy
Measured: From the date of enrolment plus 6 weeks
Secondary outcomes (4)
Patients in whom ctDNA result identified a genomically-matched SOC therapy
The number (%) of patients in whom ctDNA result identified a genomically-matched SOC therapy
Measured: From the date of enrolment plus 6 weeks
Patients in whom ctDNA result identified a genomically-matched clinical trial (based in the UK)
The number (%) of patients in whom ctDNA result identified a genomically-matched clinical trial (based in the UK)
Measured: From the date of enrolment plus 6 weeks
Patients in whom ctDNA result offered additional prognostic information not otherwise available through SOC testing
The number (%) of patients in whom ctDNA result offered additional prognostic information not otherwise available through SOC testing
Measured: From the date of enrolment plus 6 weeks
Patients in whom ctDNA result negated need for tissue biopsy
The number (%) of patients in whom ctDNA result negated need for tissue biopsy
Measured: From the date of enrolment plus 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2026
- Study start23 May 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Royal Marsden NHS Foundation TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sanjay Popat, BSc, MBBS, PhD, Principal investigator, Royal Marsden NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07673861
- Sponsor's protocol ID
- CCR6022
- Acronym
- CURTAIN
- Status last verified
- Jun 2026
- First submitted
- 19 Nov 2025
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Currently there are no plans to share individual participant data. This will be considered by the trial team, and updated in future if required.
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine: A Tumour Agnostic Study
- ClinicalTrials.gov ID
- NCT07673861
- Acronym / sponsor ID
- CURTAIN / CCR6022
- Conditions
- Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer, Ovarian Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Royal Marsden NHS Foundation TrustUniversity, hospital or other
- Study start
- 23 May 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 29 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease).
The aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK).
One hundred patients will be recruited, with 20 from each of the following cancer types:
- Non-small cell lung cancer
- Gastrointestinal stromal tumours
- Colorectal cancer
- Biliary tract cancer
- Ovarian cancer.
Patients must be aged 18 or over, must have had progressive disease whilst receiving anti-cancer treatment, and must be being treated at The Royal Marsden.
Patients will have a blood sample taken and analysed using the Marsden360 ctDNA test. The results of the test will be looked at by The Royal Marsden Genomic Tissue Advisory Board (GTAB), and for each individual patient, the GTAB will determine if having a ctDNA test helped to personalise their care by:
- Aiding the identification of a genomically-matched standard of care therapy
- Aiding the identification of a genomically-matched clinical trial (based in the UK)
- Offering additional prognostic information not otherwise available through standard of care testing
- Negating the need for a tissue biopsy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients who have had progressive disease on therapy within the 6 weeks prior to consent | Other | Diagnostic Test: Marsden360 ctDNA test and GTAB review |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (22 listed)
- Age ≥18 years old
- Ability to provide written informed consent
- Presence of metastatic or unresectable disease
- Being reviewed and treated through medical oncology service at Royal Marsden Hospital
- Cohort 1: Locally Advanced/Metastatic NSCLC
Key exclusion criteria (3 listed)
- Medically unstable to commit to sampling required for the study
- ECOG performance status ≥3
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Marsden360 ctDNA test and GTAB reviewParticipant blood samples will analysed using the Marsden360 ctDNA test. Results will subsequently be reviewed by the Royal Marsden Genomic Tumour Advisory Board (GTAB). The GTAB will use the results of the test to try to identify a genomically-matched standard of care therapy, to identify a genomically-matched clinical trial (based in the UK), to offer additional prognositc information not otherwise available through standard of case, or determine if the need for a tissue biopsy is negated. | Diagnostic test | Patients who have had progressive disease on therapy within the 6 weeks prior to consent |
Primary outcome
The number (%) of patients in whom ctDNA result was deemed to be clinically useful at the time of progression on prior line of therapy
Time frame: From the date of enrolment plus 6 weeks
This is a composite outcome measure, where the results of ctDNA testing performed at the time of progressive disease led to at least one of the following (to be determined by the GTAB): * Identification of a genomically-matched SOC therapy, or * Identification of a genomically-matched clinical trial (based in the UK), or * Offered additional prognostic information not otherwise available through SOC, or * Negated the need for a tissue biopsy
4 secondary outcomes
Patients in whom ctDNA result identified a genomically-matched SOC therapy
Time frame: From the date of enrolment plus 6 weeks
Patients in whom ctDNA result identified a genomically-matched clinical trial (based in the UK)
Time frame: From the date of enrolment plus 6 weeks
Patients in whom ctDNA result offered additional prognostic information not otherwise available through SOC testing
Time frame: From the date of enrolment plus 6 weeks
Patients in whom ctDNA result negated need for tissue biopsy
Time frame: From the date of enrolment plus 6 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: No. Currently there are no plans to share individual participant data. This will be considered by the trial team, and updated in future if required.
Related trials for Non Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sanjay Popat, BSc, MBBS, PhD principal investigator
Royal Marsden NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Marsden360 ctDNA test and GTAB review in people with Non Small Cell Lung Cancer and Gastrointestinal Stromal Tumor (GIST), run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 22 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rebecca Brooks (+44 208 642 6011, rebecca.brooks@rmh.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The number (%) of patients in whom ctDNA result was deemed to be clinically useful at the time of progression on prior line of therapy (time frame: From the date of enrolment plus 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.